PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

Pike, Christopher Gerar
PIKE & CO.
Hayes Loft
68A Hayes Place
Marlow, Buckinghamshire SL7 2BT
GRANDE BRETAGNE

PIKE & CO.
RECEIVED
- 7 JUN 2001
INIT
ATTN

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Rule 71.1)

	Date of mailing *(day/month/year)* 05.06.2001
Applicant's or agent's file reference PG3693/PCT	**IMPORTANT NOTIFICATION**

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/EP00/03515	19/04/2000	24/04/1999

Applicant
GLAXO GROUP LIMITED

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/	Authorized officer
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Miehle, S Tel.+49 89 2399-7265

Form I

Express Mail Label
EL395895194US

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
PG3693/PCT		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/EP00/03515	19/04/2000	24/04/1999
International Patent Classification (IPC) or national classification and IPC B65D75/20		
Applicant GLAXO GROUP LIMITED		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 8 sheets, including this cover sheet.

   ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 11 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☒ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
28/10/2000	05.06.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Felgenhauer, H-P Telephone No. +49 89 2399 2618

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/03515

I. Basis of the report

1. With regard to the **elements** of the international application *(Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17))*:
Description, pages:

1,2,7,8,10-16	as originally filed	
3-6,9	with telefax of	18/04/2001

Claims, No.:

1-42	with telefax of	18/04/2001

Drawings, sheets:

1/5-5/5	as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

   These elements were available or furnished to this Authority in the following language: , which is:

   - ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
   - ☐ the language of publication of the international application (under Rule 48.3(b)).
   - ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

   - ☐ contained in the international application in written form.
   - ☐ filed together with the international application in computer readable form.
   - ☐ furnished subsequently to this Authority in written form.
   - ☐ furnished subsequently to this Authority in computer readable form.
   - ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
   - ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

   (Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

   ☐ the entire international application.

   ☒ claims Nos. 41,42.

because:

   ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

   ☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
   see separate sheet

   ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

   ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

   ☐ the written form has not been furnished or does not comply with the standard.

   ☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1 - 40
	No:	Claims	
Inventive step (IS)	Yes:	Claims	18-20
	No:	Claims	1-15, 21-40
Industrial applicability (IA)	Yes:	Claims	1-40
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Item III

1. Claims 41,42 contain a reference to the drawings. According to Rule 6.2(a) PCT claims should not contain such references except where is absolutely necessary. Such is not, however, the case here.

Item V

1. The following documents are referred to
D1...US-A-3 698 549
D2...FR-A-850 597

2. Claim 1 is unclear (Article 6 PCT), cf. item VIII.

3.1 Claim 1 is directed to a combination comprising as first element a carrier, defined by structural features and having a pocket or pouch, the pocket or pouch of the carrier containing - as a second element of the combination - a unit dose of a medicament.

3.2 The shape or consistency of the medicament remaining undefined in claim 1 is defined by the additional features of claim 26.

3.3 As far as the structure of the carrier is concerned D1 and D2 disclose a carrier having the structure as defined in claim 1, cf. D1, claim 1; column 1, lines 53 - 68; figure 1 - 4 - elongate strip 11; fold 12; first and second portion 13, 14; join 19, 21 (column 2, lines 1 - 18); D2, page 2, line 95 - page 3, line 12; page 4, line 32 - 59; figures 1 - 9, especially figures 4,5.

As far as the material contained within the carrier is concerned, according to D1 flat articles, such as surgical supplies, are contained (cf. claim 1; column 1, lines 2,3; figure 7).

It is apparent that at least if a unit dose of medicament is in a form similar to the one referred to in D1 (flat article) then containment of this unit dose of medicament within the carrier according to D1 cannot be considered as involving

an inventive step, since it simply involves use of the carrier as disclosed in D1 for a product other then the one disclosed in D1, but for which - since the further use or ingredients of the product (medicament) apparently have no influence on the capability of such a carrier to contain such a product (cf. claim 1 of the application).

Since claim 1 does not specify any shape or consistency of the unit dose of medicament and since containment of a flat product of this kind is obvious in view of D1, the subject-matter of claim 1 does not involve an inventive step such that the requirement of Article 33 (3) PCT is not met.

3.4 Concerning a unit dose of medicament being of the shape/consistency as defined in claim 26 the following applies.

a) Unit dose of medicament in the form of a tablet, paste, cream or capsular form.

It is apparent that, without essential modification being required, a solid article like a tablet and a medicament in capsular form or an article of similar consistency like a paste or a cream is - irrespective of the product being held by the carrier being a medicament - containable within the carrier according to D1 (cf. e.g. the filling space provided in the pocket or pouch shown in figure 7). Consequently the corresponding features of claim 26 cannot lead to subject-matter involving inventive step, such that the requirement of Article 33 (3) PCT is not met for these alternatives of claim 26.

b) Unit dose of medicament in the form of dry powder or a liquid.

Containment of such a product is obvious in view of D2 which, as indicated above in paragraph 3.3, discloses a carrier having the structure as defined in claim 1. Since as products to be contained in such a carrier flour sugar and analogous materials are mentioned in D2 and since containment of such products in a carrier is irrespective of the later use or purpose of the product as a medicament or a nutritional product these alternative features of claim 26 likewise cannot lead to subject-matter involving inventive step (Article 33 (3) PCT).

For a corresponding reason the additional features of claim 27 being directed to a variety of medicaments cannot be considered as leading to subject-matter involving inventive step since the medicaments as such are generally known and since, as indicated above, it is obvious for such products (being in solid, powder or liquid state) being contained in a carrier as disclosed in D1 or D2.

4.1 The additional features of claims 2 - 15 and of claims 21 - 25, as far as these claims are not dependent on claim 18, concern structural details, provided depending on circumstances, which come within regular design practice starting from D1 or D2.

4.2 To have a plurality of carriers as referred to above in a series arrangement (claim 16) and furthermore the carriers connected together (claim 17) is obvious in view of D1 or D2 since it does not involve inventive step to form a series arrangement of carriers, as such not involving an inventive step, and since, depending on circumstances, it is obvious to connect a plurality of carriers - e.g. by provision of glue spots - together.

4.3 Claim 18 being directed to a series arrangement of a plurality of carriers connected together and **formable from the same elongate strip** is not suggested by the prior art since neither D1 nor D2 nor one of the remaining documents cited in the International Search Report suggests such a series arrangement. Thus claim 18 should satisfy the requirement of Article 33 (3) PCT.

This applies correspondingly with regard to the further developments according to claims 19, 20 and for any of the remaining claims as far as they are dependent on claim 18.

4.3 As far as claims 28 - 40 are not dependent on claim 18 they cannot be considered as involving an inventive step (Article 33 (3) PCT) for the reason given above with respect to claim 1 and its dependent claims.

Item VII

1.1 Each independent claim should have been properly cast in the two-part form (Rule 6.3 (b) PCT).

1.2 Reference signs in parentheses should have been inserted in the claims to increase their intelligibility, Rule 6.2(b) PCT. This applies to both the preamble and characterising portion.

1.3 To meet the requirements of Rule 5.1(a)(ii) PCT, the documents D1 and D2 should have been identified in the description and the relevant background art disclosed therein should have been briefly discussed.

Item VIII

1. Claim 1 is not clear (Article 6 PCT) since for the fold to be made it appears to be essential that the elongate strip is flexible. Consequently the additional feature of claim 21 is missing as an essential feature.

2. The general statements in the description at page 16, paragraphs 2, 3 are not clear, and when used to interpret the claims renders them also unclear, contrary to Article 6 PCT. These statements should therefore be deleted.

invention is particularly suitable for such use, as will be shown in embodiments, because the individual medicament containers have the ability to lie flat against the elongate strip thus forming a compact series of medicament containers.

Another advantage provided by the present invention is that the use of the flat medicament container allows air to pass over the whole container surface when opened thereby improving drug removal. The design of the carrier has the further advantage that it reduces drug loss, caused by drug adherence to the top of conventional carriers when these are discarded on opening the carrier, by making all of the drug available for delivery to the patient.

It is an additional object of the present invention to provide a simple means of packaging, presenting and accessing a variety of non-medical products, including food, beverages, disinfectants, toiletries, electrical, photographic and printing products, as will be shown in the embodiments described herein.

According to one aspect of the present invention there is provided a carrier comprising an elongate strip having a first portion and a second portion; a fold between said first portion and said second portion such that the first portion contacts the second portion; and a join between the first portion and the second portion, wherein said join and the fold form the edges of a pocket or pouch for containment of ~~product~~ medicament, the pocket or pouch containing a unit dose of medicament therein.

In one aspect there is provided a carrier wherein the pocket or pouch comprises folds therein. In another aspect, the pocket or pouch comprises contours or ridges therein.

In another aspect, there is provided a carrier additionally comprising a retainer within the pocket or pouch for retaining ~~product~~ medicament thereon. The retainer is for example, a mesh or sponge.

In a further aspect, each of the ends of the elongate strip has a non self-binding adhesive portion allowing reversible contact therebetween. Preferably each of the ends of the elongate strip has a peelable cover thereon. More preferably, removal of the peelable cover reveals an adhesive portion on each of the ends of the elongate strip. Most preferably, the adhesive portion enables attachment of the carrier to mammalian skin. Thus the carrier can be directly applied to the skin to administer medicament to the patient, thereby providing a simplified system for topical treatments with medicament and minimal risk of contamination or loss of medicament through non-target contact.

In one aspect, there is provided a carrier comprising at least one further join forming at least one further pocket or pouch for containment of ~~product~~ medicament.

In a further aspect, there is provided a carrier wherein the ends of the elongate strip form a pair of pull release tabs. Preferably each of the pull release tabs is shaped for ease of grip. More preferably, each of the pull release tabs has a looped end. Most preferably, each of the pull release tabs has at least one perforation therein.

In another aspect, there is provided a carrier additionally comprising a drawstring opening mechanism. Preferably the carrier comprises protruding release ends of the drawstring for opening thereof.

In a further aspect, there is provided a carrier in multi-unit form comprising a series arrangement of a plurality of carriers as described above. Preferably each of the carriers is connected together. More preferably, each of the plurality of carriers is formable from the same elongate strip. Most preferably, the strip has a point of weakness between each carrier in the series arrangement. Suitably, each pocket or pouch is foldable to lie flat alongside the elongate strip.

In one aspect, there is provided a carrier wherein the elongate strip is flexible. Preferably the elongate strip comprises material selected from the group consisting

of metal foil, an organic polymeric material and paper. More preferably, the strip comprises a laminate.

In another aspect, there is provided a carrier wherein the join is formable by a joining method selected from the group consisting of heat, laser, radio frequency, adhesive, staple, stamp, pressure and ultrasonic sealing. Suitably the join is peelable to enable peelable access to the pocket or pouch.

~~In a further aspect, there is provided a carrier comprising a medicament therein.~~ Preferably the medicament is in dry powder, tablet, liquid, paste, cream or capsular form. More preferably the medicament is selected from the group consisting of albuterol, salmeterol, ipratropium bromide, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof and any mixtures thereof.

According to another aspect of the present invention, there is provided an inhalation device comprising a housing in combination with a medicament carrier as described above. Preferably the inhalation device comprises a release mechanism and the carrier comprises a pair of pull release tabs connected to the release mechanism. More preferably, the release mechanism is separable from the housing of the inhalation device.

According to a further aspect of the present invention, there is provided a method of making a carrier comprising forming a fold between a first portion and second portion of an elongate strip such that the first portion contacts the second portion; forming a join between the first portion and the second portion wherein the join and the fold form the edges of an open pocket or pouch for containment of ~~product~~ medicament; filling the open pocket or pouch with the ~~product~~ unit dose of medicament; and closing the open pocket or pouch by forming a further join.

BEST AVAILABLE COPY

Preferably there is provided a method of making a carrier in multi-unit form comprising successive iterations of the method described above to form a series arrangement of a plurality of carriers.

According to another aspect of the present invention, there is provided a method of opening a carrier as described above comprising pulling the pair of pull release tabs in order to enable access to the pouch.

In a further aspect of the present invention, there is provided the use of a carrier, as described above, for dispensing medicament. Preferably the use of the carrier is for applying medicament to skin. More preferably, the use is for the treatment of cuts, abrasions or infections of skin. Optionally, the use is for dispensing slow-release formulations of medicaments via the skin.

In a preferred aspect, the medicament is used in the treatment of respiratory disorders. More preferably the medicament is used in the treatment of asthma. Most preferably the medicament is salbutamol or albuterol.

In one aspect, there is provided a carrier comprising an electronic component therein. Preferably the electronic component is selected from the group consisting of semi-conductor, integrated circuit chip, fuse and battery.

In another aspect, there is provided a carrier comprising a food therein. Preferably the food is selected from the group consisting of meat, mycoprotein, milk, cheese, flour, pasta, rice, oil, sugar, confectionery, vegetable, herbal, snack, convenience and fruit foodstuffs.

In a further aspect, there is provided a carrier comprising a beverage therein. Preferably the beverage is selected from the group consisting of water, milk, coffee, cocoa, tea, fruit, carbonated and alcoholic drinks.

BEST AVAILABLE COPY

group consisting of spermacide, estrogen, ethinyl estradiol, progesterone, levonorgestrel and norgestrel.

In one aspect, there is provided a carrier comprising a medical instrument therein. Preferably the medical instrument is selected from the group consisting of scalpel, thermometer and syringe.

In another aspect, there is provided a carrier comprising laboratory equipment therein. Preferably the equipment is selected from the group consisting of dispenser tip, microbial filter, filter paper, aseptic container, petri-plate, vial, test tube, tissue-culture vessel and pipette.

In a further aspect, there is provided a carrier comprising a catemenial product therein. Preferably the catemenial product comprises a tampon.

In one aspect, there is provided a carrier comprising nicotine therein.

Preferred embodiments of the medicament carrier according to the present invention will now be described with reference to the accompanying drawings in which:

Figure 1a is a perspective sideview of a first medicament carrier in accordance with the present invention in the closed and perpendicular configuration.

Figure 1b is a perspective sideview of the first medicament carrier in accordance with the present invention in the open configuration.

Figure 1c is a perspective sideview of a second medicament carrier in accordance with the present invention in the closed and perpendicular configuration.

Figure 1d is a perspective sideview of the second medicament carrier in accordance with the present invention in the open configuration.

BEST AVAILABLE COPY

10/031637

331 Rec'd PCT 26 OCT 2001

Claims

1. A carrier comprising an elongate strip having a first portion and a second portion; a fold between said first portion and said second portion such that the first portion contacts the second portion; and a join between the first portion and the second portion, wherein said join and the fold form the edges of a pocket or pouch for containment of ~~product~~ medicament, said pocket or pouch containing a unit dose of medicament therein.

2. A carrier according to claim 1, wherein said pocket or pouch comprises folds therein.

3. A carrier according to either of claims 1 or 2, wherein said pocket or pouch comprises contours or ridges therein.

4. A carrier according to any of claims 1 to 3, additionally comprising a retainer within the pocket or pouch for retaining medicament/~~product~~ thereon.

5. A carrier according to any of claims 1 to 4, wherein each of the ends of the elongate strip has a non self-binding adhesive portion.

6. A carrier according to any of claims 1 to 5, wherein each of the ends of the elongate strip has a peelable cover thereon.

7. A carrier according to claim 6, wherein removal of said peelable cover reveals an adhesive portion on each of the ends of the elongate strip.

8. A carrier according to any of claims 5 to 7, wherein the adhesive portion enables attachment of the carrier to mammalian skin.

BEST AVAILABLE COPY

9. A carrier according to any of claims 1 to 8 comprising at least one further join forming at least one further pocket or pouch for containment of ~~product~~ medicament.

10. A carrier according to any of claims 1 to 9, wherein the ends of the elongate strip form a pair of pull release tabs.

11. A carrier according to claim 10, wherein each of said pull release tabs is shaped for ease of grip.

12. A carrier according to either of claims 10 or 11, wherein each of the pull release tabs has a looped end.

13. A carrier according to any of claims 10 to 12, wherein each of the pull release tabs has at least one perforation therein.

14. A carrier according to any of claims 1 to 13, additionally comprising a drawstring opening mechanism.

15. A carrier according to claim 14, additionally comprising protruding release ends of said drawstring for opening thereof.

16. A carrier in multi-unit form comprising a series arrangement of a plurality of carriers according to any of claims 1 to 15.

17. A carrier according to claim 16, wherein each of said plurality of carriers is connected together.

18. A carrier according to claim 17, wherein each of said plurality of carriers is formable from the same elongate strip.

BEST AVAILABLE COPY

19. A carrier according to claim 18, wherein said strip has a point of weakness between each carrier in said series arrangement.

20. A carrier according to any one of claims 16 to 19, wherein each pocket or pouch is foldable to lie flat alongside the elongate strip.

21. A carrier according to any claims 1 to 20, wherein the elongate strip is flexible.

22. A carrier according to any of claims 1 to 21, wherein the elongate strip comprises material selected from the group consisting of metal foil, an organic polymeric material and paper.

23. A carrier according to claim 22, wherein the strip comprises a laminate.

24. A carrier according to any one of claims 1 to 23, wherein the join is formable by a joining method selected from the group consisting of heat, laser, radio frequency, adhesive, staple, stamp, pressure and ultrasonic sealing.

25. A carrier according to any one of claims 1 to 18, wherein the join is peelable to enable peelable access to the pocket or pouch.

~~26. A carrier according to any of claims 1 to 25, comprising a medicament therein.~~

any of 1-25

26 ~~27~~. A carrier according to ~~claims~~ claim ~~26~~, wherein said medicament is in dry powder, tablet, liquid, paste, cream or capsular form.

any 1 to 26 the

27 ~~28~~. A carrier according to ~~either~~ of claims ~~26 or 27~~, wherein ~~said~~ medicament is selected from the group consisting of albuterol, salmeterol, ipratropium bromide, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof and any mixtures thereof.

BEST AVAILABLE COPY

28. ~~29.~~ An inhalation device comprising a housing in combination with a medicament carrier as claimed in any of claims ~~28~~ 1 to ~~28~~ 27.

29 ~~30.~~ An inhalation device according to claim ~~29~~ 28, wherein the inhalation device comprises a release mechanism and the carrier comprises a pair of pull release tabs connected to said release mechanism.

30 ~~31.~~ An inhalation device according to claim ~~30~~ 29, wherein the release mechanism is separable from the housing of the inhalation device.

31 ~~32.~~ A method of making a carrier comprising forming a fold between a first portion and second portion of an elongate strip such that said first portion contacts said second portion; forming a join between said first portion and said second portion wherein said join and the fold form the edges of an open pocket or pouch for containment of ~~product~~ medicament; filling said open pocket or pouch with a unit dose of medicament ~~said product~~; and closing said open pocket or pouch by forming a further join.

32 ~~33.~~ A method of making a carrier in multi-unit form comprising successive iterations of the method of claim ~~32~~ 31 to form a series arrangement of a plurality of carriers.

33 ~~34.~~ A method of opening a carrier as claimed in claims 10 to ~~28~~ 27 comprising pulling the pair of pull release tabs in order to enable access to the pouch.

34 ~~35.~~ Use of a carrier according to any of claims ~~28~~ 1 to ~~28~~ 27, for dispensing medicament.

35 ~~36.~~ Use of a carrier according to claim ~~35~~ 34, for applying medicament to skin.

36 ~~37.~~ Use of a carrier according to claim ~~36~~ 35, for the treatment of cuts, abrasions or infections of said skin.

BEST AVAILABLE COPY

80. A carrier according to claim 78, wherein said contraceptive drug is selected from the group consisting of spermacide, estrogen, ethinyl estradiol, progesterone, levonorgestrel and norgestrel.

81. A carrier according to any of claims 1 to 25, comprising a medical instrument therein.

82. A carrier according to claim 81, wherein said medical instrument is selected from the group consisting of scalpel, thermometer and syringe.

83. A carrier according to any of claims 1 to 25, comprising laboratory equipment therein.

84. A carrier according to claim 83, wherein said equipment is selected from the group consisting of dispenser tip, microbial filter, filter paper, aseptic container, petri-plate, vial, test tube, tissue-culture vessel and pipette.

85. A carrier according to any of claims 1 to 25, comprising a catemenial product therein.

86. A carrier according to claim 85, wherein said catemenial product comprises a tampon.

~~87. A carrier according to any of claims 1 to 25, comprising nicotine therein.~~

88. A carrier as substantially herein described with reference to the accompanying drawings.

~~89~~. An inhalation device as substantially herein described with reference to the accompanying drawings.

BEST AVAILABLE COPY